Background: Saline nasal irrigation is labelled as an add-on treatment in patients with allergic rhinitis (AR). The primary aim of this study was to compare the efficacy of 21-day use of buffered hypertonic saline (BHS) versus normal saline solution (NSS) on reducing nasal symptoms in children with seasonal AR (SAR). Comparing their efficacy on nasal cytology counts (NCC), quality of life, and sleep quality was the secondary aim. Methods: In this 21-day, o pen-label, randomized controlled study, 36 SAR children (aged 6–13 years) with a Total 5 Symptom Score (T5SS) ≥ 5 received twice-daily BHS or NSS delivered through a nasal douche. Efficacy measures were least square mean changes (LSmc) in T5SS, NCC, Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), and Pittsburgh Sleep Quality Index (PSQI) scores. Results: BHS improved the T5SS total score to a greater extent than NSS (LSmc –6.45 vs. –5.45, p < 0.001). Concerning NCC, BHS significantly reduced the scores of neutrophils (LSmc –0.76, p = 0.004) and eosinophils (LSmc –0.46, p = 0.018), while NSS did not. Similarly, only BHS yielded a significant improvement in the PRQLQ score (LSmc –0.57, p = 0.009), whereas the improvement in PSQI score was comparable between the BHS (LSmc –0.77, p = 0.025) and NSS (LSmc –1.39, p < 0.001) groups. Overall, BHS was well tolerated. Conclusions: In children with SAR, BHS is effective in improving nasal symptoms and NCC, with an associated beneficial effect on quality of life

Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial

Ferrante G;
2017

Abstract

Background: Saline nasal irrigation is labelled as an add-on treatment in patients with allergic rhinitis (AR). The primary aim of this study was to compare the efficacy of 21-day use of buffered hypertonic saline (BHS) versus normal saline solution (NSS) on reducing nasal symptoms in children with seasonal AR (SAR). Comparing their efficacy on nasal cytology counts (NCC), quality of life, and sleep quality was the secondary aim. Methods: In this 21-day, o pen-label, randomized controlled study, 36 SAR children (aged 6–13 years) with a Total 5 Symptom Score (T5SS) ≥ 5 received twice-daily BHS or NSS delivered through a nasal douche. Efficacy measures were least square mean changes (LSmc) in T5SS, NCC, Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), and Pittsburgh Sleep Quality Index (PSQI) scores. Results: BHS improved the T5SS total score to a greater extent than NSS (LSmc –6.45 vs. –5.45, p < 0.001). Concerning NCC, BHS significantly reduced the scores of neutrophils (LSmc –0.76, p = 0.004) and eosinophils (LSmc –0.46, p = 0.018), while NSS did not. Similarly, only BHS yielded a significant improvement in the PRQLQ score (LSmc –0.57, p = 0.009), whereas the improvement in PSQI score was comparable between the BHS (LSmc –0.77, p = 0.025) and NSS (LSmc –1.39, p < 0.001) groups. Overall, BHS was well tolerated. Conclusions: In children with SAR, BHS is effective in improving nasal symptoms and NCC, with an associated beneficial effect on quality of life
Buffered hypertonic solution
Children
Nasal cytology
Quality of life
Nasal symptoms
Seasonal allergic rhinitis
File in questo prodotto:
File Dimensione Formato  
MAlizia_IntArchAllergyImmunol2017_Efficacy of Buffered Hypertonic Saline Nasal.pdf

non disponibili

Dimensione 182.91 kB
Formato Adobe PDF
182.91 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11562/1050484
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 16
social impact